CME: New Strategies for the Treatment and Management of Anticoagulant Bleeding - online enduring - NATF
ACCREDITATION EXPIRED: April 30, 2021
Activity Description / Statement of Need:
The content of this online activity was presented originally at a live event. It is divided into three videos. Learners must view all three in their entirety and complete a post-activity assessment and evaluation before they are eligible for continuing credit.
The North American Thrombosis Forum’s (NATF’s) “New Strategies for the Treatment and Management of Anticoagulant-Associated Bleeding” offers attendees insight into the most recent medical research and innovation in protecting patients at risk for anticoagulant-associated bleeding. The activity, taught by world thought leaders, will focus on educating healthcare providers who treat patients on—or who are a candidate for—anticoagulation. We welcome world-class experts in cardiology, hematology, vascular medicine, and pharmacy to update us on this challenging topic.
Although there are many new anticoagulants available, there are few advancements in how to manage and treat patients at risk for major bleeding. This program focuses on bleeding risks associated with DOACs and warfarin. Experts discuss novel approaches for managing bleeding risks in vulnerable patients, patients in need of a procedure, and best practices for anticoagulant treatment options. This activity includes real-life patient cases and concludes with a discussion and Q&A.
Target Audience:
Physicians, pharmacists, nurses, physician assistants, and nurse practitioners who specialize in cardiology or hematology and any other health professional, patient, or family member with an interest in anticoagulant-associated bleeding.
Participation in this activity is made possible, free of charge, with the support of Portola Pharmaceuticals.
Release Date: May 01, 2020 -- Expiration Date: April 30, 2021
Faculty: Multiple Faculty,
Agenda
Video 1
|
Anticoagulation-Associated Bleeding: An Enemy Hiding in Plain Sight – Christian T. Ruff, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Director of General Cardiology Division, Brigham and Women’s Hospital, Boston, MA |
|
Warfarin isn’t Going Away, and Neither is Warfarin-Associated Bleeding – Gregory Piazza, MD, MS, Associate Professor of Medicine, Harvard Medical School; Staff Physician, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA |
Video 2
|
The Blessing and Curse of Direct Oral Anticoagulants (DOACs): Management of DOAC-Associated Bleeding – Jean Connors, MD, Assistant Professor of Medicine, Harvard Medical School; Hematology Attending, Medical Director Hemostatic Antithrombotic Stewardship and Anticoagulation Management Services, Brigham and Women’s Hospital, Boston, MA |
|
Critical Pathways for the Assessment of Anticoagulants in the Bleeding Patient – Nathan T. Connell, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Hematology Division, Brigham and Women’s Hospital, Boston, MA |
Video 3
|
My Patient is not Bleeding but Needs a Procedure – Umberto Campia, MD, MS, Assistant Professor of Medicine, Harvard Medical School, Associate Physician, Brigham and Women’s Hospital, Boston, MA |
|
An Ounce of Prevention: Strategies for Safe Anticoagulation in Vulnerable Patients – Katelyn W. Sylvester, PharmD, CACP, BCPS, Pharmacy Manager – Anticoagulation Services; PGY1 Pharmacy Residency Coordinator, Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA |
|
Panel Discussion and Q&A |
Video 1
|
Anticoagulant Associated Bleeding: An Enemy Hiding in Plain Sight – Christian T. Ruff, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Director of General Cardiology Division, Brigham and Women’s Hospital, Boston, MA |
|
Warfarin isn’t Going Away, and Neither is Warfarin-Associated Bleeding – Gregory Piazza, MD, MS, Assistant Professor of Medicine, Harvard Medical School; Staff Physician, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA |
Video 2
|
The Blessing and Curse of Direct Oral Anticoagulants (DOACs): Management of DOAC Associated-Bleeding – Jean Connors, MD, Assistant Professor of Medicine, Harvard Medical School; Hematology Attending, Medical Director Hemostatic Antithrombotic Stewardship and Anticoagulation Management Services, Brigham and Women’s Hospital, Boston, MA |
|
Critical Pathways for the Assessment of Anticoagulants in the Bleeding Patient – Nathan T. Connell, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Hematology Division, Brigham and Women’s Hospital, Boston, MA |
Video 3
|
My Patient is not Bleeding but Needs a Procedure – Umberto Campia, MD, MS, Assistant Professor of Medicine, Harvard Medical School, Associate Physician, Brigham and Women’s Hospital, Boston, MA |
|
An Ounce of Prevention: Strategies for Safe Anticoagulation in Vulnerable Patients – Katelyn W. Sylvester, PharmD, CACP, BCPS, Pharmacy Manager – Anticoagulation Services PGY1 Pharmacy Residency Coordinator, Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA |
|
Panel Discussion and Q&A |
Learning Objectives
By the end of the session the participant will be able to:
- Recall and define risk factors for perioperative thrombotic risk and anticoagulant-associated bleeding
- List strategies to prevent or minimize anticoagulation-associated bleeding and apply them to patient cases
- Summarize approaches to the management of bleeding and thrombotic risk in anticoagulated patients requiring invasive procedures
- Describe when to use anticoagulation reversal agents
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
Christian T. Ruff, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Director of General Cardiology Division, Brigham and Women’s Hospital, Boston, MA, discloses research/grant through institution: Boehringer Ingelheim, Daiichi Sankyo, MedImmune, National Institutes of Health; honoraria for scientific advisory boards and consulting: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola, and Anthos.
Dr. Ruff is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences.
Gregory Piazza, MD, MS, Associate Professor of Medicine, Harvard Medical School; Staff Physician, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, discloses grant/research support from BMS, Portola, BTG/EKOS, Janssen, Bayer, and Daiichi-Sankyo and is a consultant for Pfizer, Amgen, and Thrombolex.
Jean Connors, MD, Assistant Professor of Medicine, Harvard Medical School; Hematology Attending, Medical Director Hemostatic Antithrombotic Stewardship and Anticoagulation Management Services, Brigham and Women’s Hospital, Boston, MA discloses being a consultant with Bristol-Myers Squibb, part of a scientific advisory board for Portola, and having received grant/research support from CSL Behring.
|
Nathan T. Connell, MD, MPH, Assistant Professor of Medicine, Harvard Medical School; Associate Physician, Hematology Division, Brigham and Women’s Hospital, Boston, MA, has no conflicts of interest to disclose. |
Umberto Campia, MD, MS, Assistant Professor of Medicine, Harvard Medical School, Associate Physician, Brigham and Women’s Hospital, Boston, MA, has no conflicts of interest to disclose.
|
Katelyn W. Sylvester, PharmD, CACP, BCPS, Pharmacy Manager – Anticoagulation Services; PGY1 Pharmacy Residency Coordinator, Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, discloses that she is a consultant for Portola Pharmaceuticals. |
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Managing Cardiovascular Risk in Women Updated Guidance
Advances in the management of Fabry disease
Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies